<DOC>
	<DOCNO>NCT01532115</DOCNO>
	<brief_summary>The purpose study evaluate effect BIA 9-1067 cardiac repolarization adult healthy men woman volunteer .</brief_summary>
	<brief_title>Effect BIA 9-1067 Cardiac Repolarization Healthy Adult Men Women</brief_title>
	<detailed_description>Single-centre , randomize , double-blind , placebo-controlled open-label active-controlled , 4-period crossover trial healthy male female subject</detailed_description>
	<mesh_term>Parkinson Disease</mesh_term>
	<mesh_term>Opicapone</mesh_term>
	<mesh_term>Moxifloxacin</mesh_term>
	<mesh_term>Fluoroquinolones</mesh_term>
	<mesh_term>Norgestimate , ethinyl estradiol drug combination</mesh_term>
	<criteria>A sign date informed consent form studyspecific screen procedure perform , Healthy male female 18 55 year age . Women postmenopausal ( 12 month since last period ) ; surgically sterile ( hysterectomy tubal ligation bilateral oophorectomy least 6 month prior enrollment ) ; use intrauterine device ; nonhormonal double barrier contraceptive method ( i.e. , diaphragm spermicide plus male condom ) duration trial negative pregnancy test screen upon checkin study facility , Had BMI within range 1830 kg/m2 , Able communicate effectively study personnel , Had significant disease abnormal laboratory value determine medical history , physical examination laboratory evaluation , conduct screen visit admission clinic , Had normal 12lead electrocardiogram , without clinically significant abnormality rate , rhythm conduction , Nonsmokers exsmokers least 3 month , Adequately informed nature risk study give write informed consent prior study entry . Known hypersensitivity allergy moxifloxacin , BIA 91067 related compound tolcapone entacapone , Women pregnant breastfeeding , Any disease condition ( medical surgical ) , opinion Investigator , might compromise hematologic , cardiovascular , pulmonary , renal , gastrointestinal , hepatic , central nervous system ; condition might interfere absorption , distribution , metabolism excretion study drug , would place subject increase risk , A sustain supine systolic blood pressure &gt; 140 mmHg &lt; 100 mmHg diastolic blood pressure &gt; 95 mmHg screen baseline , A rest ECG heart rate &lt; 50 bpm &gt; 100 bpm , An abnormal screening ECG indicate second thirddegree AV block , one following : QRS &gt; 110 millisecond ( m ) , QTc ( Fridericia correction ) &gt; 450 m male 470 m female , PR interval &gt; 240 ms. Any rhythm sinus rhythm , interpret Investigator clinically significant , The presence abnormal laboratory value consider clinically significant Investigator , Positive screen Hepatitis B ( HbsAg , Hepatitis B Surface Antigen ) , Hepatitis C ( anti HCV , Hepatitis C Antibody ) , HIV ( antiHIV 1/2 ) , Received investigational drug within period 30 day prior enrolment study , Received drug therapy , exclude hormonal contraceptive , within 2 week prior administration first dose studyrelated treatment . This exclusion extend 4 week drug know induce inhibit hepatic drug metabolism , Consumption alcohol within 48 hour prior dose administration inpatient period , A positive urine drug screen include positive alcohol breath test , Any history alcohol abuse , illicit drug use , significant mental illness , physical dependence opioid , history drug abuse addiction , A history difficulty donate blood , Donated blood blood product within 45 day prior enrollment , History tendonitis tendon rupture associate treatment quinolone antibiotic , Subjects , history , additional risk factor Torsades de Pointes ( e.g. , heart failure , hypokalemia ) , family history long QT syndrome family history sudden death .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>June 2012</verification_date>
	<keyword>Parkinson Disease</keyword>
	<keyword>BIA 9-1067</keyword>
</DOC>